Lu, Shan

Lu Shan is a researcher in the field of cancer metabolism. Her work focuses on understanding the role of metabolic enzymes in cancer cell metabolism and tumorigenesis. Specifically, she has studied tyrosine catabolism and its impact on acetyl-CoA levels and histone acetylation, leading to suppression of G6PD expression. She has also revealed that an exogenous acetate supplement rapidly increases G6PD expression in HPD knockdown cells, but it cannot totally rescue the decreased G6PD expression. Her findings suggest that HDAC10 is responsible for the G6PD expression through regulating histone acetylation modification. Lu Shan's research has implications in developing new strategies for cancer prevention and treatment.

Biography:  https://www.nature.com/articles/s41419-019-1756-1

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

First Human Production of Elusive HIV Antibodies in Groundbreaking Vaccine Trial

First Human Production of Elusive HIV Antibodies in Groundbreaking Vaccine Trial

Broke On: Friday, 17 May 2024 Scientists have reported success in triggering the production of rare and elusive antibodies against HIV in human patients for the first time, using a novel vaccine approach. Another innovative strategy involves selectively activating rare B cells to produce broadly neutralizing antibodies. While these advancements offer hope for an eventual HIV vaccine, researchers emphasize continued exploration and building on recent successes to develop a safe and effective solution.